AmMax Partnering

AmMax is built on the partnership with Amgen via the licensing of a potent monoclonal antibody targeting CSF1R. We plan to continue to build out the dual anti-inflammatory/anti-fibrotic CSF1R technology platform through research collaborations.

LifeMax licensed the worldwide rights to AMG820, now designated AMB-05X, which is in clinical development for tenosynovial giant cell tumor (AMB-051 program). The same molecule is also being developed for idiopathic pulmonary fibrosis (AMB-053), polycystic kidney diseases (AMB-055) and an undisclosed indication (AMB-057).